

Health Care Utilization and Respiratory Status Following the Addition of a Portable Non-Invasive Open Ventilator (NIOV) to the Treatment Regimen

Morishige, R¹; Farberow, K²; MacIntyre, N³

¹ Clinical Research Consulting, Castro Valley, CA

² SCIO Health Analytics, West Hartford, CT

³ Duke University Medical Center, Durham, NC

Presented at CHEST 2015

STUDY DESIGN

Retrospective analysis of 16 stable oxygen-dependent patients with moderate to severe chronic lung disease

COLLECTED DATA

- Diagnosis, demographic/clinical characteristics
- Respiratory function
- Physician visits, ER visits, hospital and ICU admissions
- Inpatient and ICU days, mechanical ventilation days
- 2 patient-reported measures of respiratory status (CAT and mMRC)

RESULTS

- Statistically significant health care utilization across four of five health care utilization measures: emergency room visits, hospital days, hospital ICU days and mechanical ventilations.
- Estimated total cost reductions across the study population of between 68 and 96 percent. Office visits were the only measure that did not achieve significant decreases in frequency or cost.
- COPD Assessment Test (CAT) and modified Medical Research Council (mMRC) scores improved significantly in the post-NIOV implementation period ($p < 0.0001$ and $p = 0.0001$, respectively).

HEALTH CARE UTILIZATION & PROJECT COST DATA PRE- AND POST-NIOV SYSTEM USE

Type of Service	Assumed Cost Per Service (USD)	Pre-NIOV Mean	Pre-NIOV Mean Cost (USD)	Post-NIOV Mean	Post-NIOV Mean Cost (USD)	Pre-NIOV Mean Total Cost (16 patients)	Post-NIOV Mean Total Cost (16 patients)	Mean Total Cost Reduction (%)
Office Visit ⁱ	305	5.4	1,647	5.9	1,800	26,352	28,792	9%
Emergency Room Visits ^{ii, iii}	800	1.9	1,520	0.6	480	24,320	7,680	-68%
Hospital Days ^{i, ii, iv}	1,500	7.6	11,400	1.3	1,950	182,400	31,200	-83%
Hospital ICU Days ^{i, v}	3,000	2.6	7,800	0.3	900	124,800	14,400	-88%
Mechanical Ventilations ^{vi}	800	2.6	2,080	0.1	80	33,820	1,280	-96%

CONCLUSIONS

In this group of ambulatory patients with chronic respiratory insufficiency, introduction of the NIOV System was associated with significantly decreased utilization of inpatient health care services and improved self-reported respiratory status.

ⁱ Dalal, A.A., Christensen, L., Liu, F., Riedel, A.A., 2010. Direct costs of chronic obstructive pulmonary disease among managed care patients. *Int J Chron Obstruct Pulmon Dis* 5, 341–349. doi:10.2147/COPD.S13771

ⁱⁱ Dalal, A.A., Shah, M., D'souza, A.O., Rane, P., 2010. Costs of inpatient and emergency department care for chronic obstructive pulmonary disease in an elderly Medicare population. *Journal of Medical Economics* 13, 591–598. doi:10.3111/13696998.2010.521734

ⁱⁱⁱ http://meps.ahrq.gov/mepsweb/data_files/publications/st318/stat318.pdf

^{iv} Wier, L.M., Elixhauser, A., Pfuntner, A., & Au, D.H. (2011, February). Overview of Hospitalizations among Patients with COPD, 2008.

Retrieved from <http://www.hcup-us.ahrq.gov/reports/statbriefs/sb106.jsp>

^v Dalal, A.A., Shah, M., D'Souza, A.O., Rane, P., 2011. Costs of COPD exacerbations in the emergency department and inpatient setting. *Respiratory Medicine* 105, 454–460. doi:10.1016/j.rmed.2010.09.003

^{vi} Nava, S., Evangelisti, I., Rampulla, C., Compagnoni, M.L., Fracchia, C., Rubini, F., 1997. Human and financial costs of noninvasive mechanical ventilation in patients affected by COPD and acute respiratory failure. *Chest* 111, 1631–1638. doi:10.1378/chest.111.6.1631

Improvements in the Health Status of Patients with Respiratory Insufficiency with the Use of a Non-Invasive Open Ventilation System (NIOV)

Carlin, BW¹; Casey, L²; Faberow, K³

¹ Drexel University School of Medicine, Pittsburgh, PA

² Mayo Clinic Health System, Franciscan Healthcare, La Crosse, WI

³ SCIO Health Analytics, West Hartford, CT

Presented as a late-breaking abstract at CHEST 2014

STUDY DESIGN

- Retrospective analysis of 21 patients with chronic lung disease*
- Comparison of CAT and mMRC dyspnea scores pre- and post-NIOV System use
- Patients used standard therapy** plus the NIOV System for 10.2 months

RESULTS
more than

50% reduction in
CAT and mMRC
scores

	Pre-NIOV	Post-NIOV
Average CAT score	26.71	12.33
Average mMRC dyspnea score	3.38	1.43

ABOUT CAT & mMRC

COPD Assessment Test (CAT) is a short, simple, patient-completed health status tool developed to assist patients and their clinicians to quantify the impact of COPD on patients' health. The CAT is validated via scientific development process as well as clinical research studies and has properties very similar to much more complex health status questionnaires such as the St. George Respiratory Questionnaire (SGRQ).¹ A CAT score can range between 0-40 with a score of 10-20 representing medium, 20-30 high, and 30-40 representing very high impact level. The CAT score has also been shown to provide a reliable score of exacerbation severity—the higher CAT scores resulted in higher exacerbation severity.² The minimum clinically important difference (MCID) of the CAT is estimated to be ≥ 2 points.³

The Medical Research Council (MRC) and the modified Medical Research Council (mMRC) scales are well established and frequently used clinical tools for determination of dyspnea. The mMRC and MRC are very similar in format and outcomes when used to measure severity of dyspnea. Variations of 1 point in the MRC scale have been shown to signify a perceived clinical improvement.⁴

* A group of 21 patients had a variety of chronic lung diseases including COPD, alpha-1 antitrypsin, bronchiolitis obliterans and pulmonary hypertension
** Standard therapy included prescription medications, oxygen and other equipment as prescribed by a physician

¹ Jones et al. 2009

² MacKay et al. 2009

³ Kon et al. 2014

⁴ Crisafulli et al. 2010

Breathe



www.breathetechnologies.com

PM-00-0064 D